{"id":"W2971538989","doi":"10.1053/j.gastro.2019.08.043","title":"Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Ulcerative Colitis","year":2019,"lang":"en","type":"article","venue":"Gastroenterology","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":221,"is_retracted":false,"has_abstract":true,"ca_institutions":"Robarts Clinical Trials; Western University","funders":"Genentech; Atlantic Healthcare; Ferring Pharmaceuticals; Otsuka America; Ipsen Biopharmaceuticals; Celgene; Novo Nordisk; Teva Pharmaceutical Industries; EA Pharma Co., Ltd.; Gilead Sciences; AbbVie; Merck; Sanofi; Takeda Pharmaceuticals U.S.A.; Tillotts Pharma; Hospira; Amgen; Pfizer; Shire; Eli Lilly and Company","keywords":"Ulcerative colitis; Medicine; Randomized controlled trial; Internal medicine; Gastroenterology; Phase (matter); Colitis; Chemistry; Disease","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001824163,0.0001147479,0.000419793,0.00006164553,0.00000978268,0.000001885693,0.00007721846,0.00004652795,0.00002419615],"category_scores_gemma":[0.00004617434,0.0000948768,0.00003814637,0.00002787124,0.000151827,0.000003234303,0.00006807214,0.00004856148,7.623614e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000007096744,"about_ca_system_score_gemma":0.00002285199,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001326132,"about_ca_topic_score_gemma":0.0002607364,"domain_scores_codex":[0.9987913,0.0004031727,0.0003332558,0.0002283153,0.00008092952,0.0001630689],"domain_scores_gemma":[0.9994593,0.00002356092,0.0001786916,0.0002090109,0.00008725623,0.00004223145],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.5389985,0.001074119,0.4589224,0.00002006509,0.0001277816,0.000006844971,0.0002843784,0.00003545828,0.0004447382,0.000007347471,0.000006351203,0.00007195453],"study_design_scores_gemma":[0.3384908,0.003354028,0.6578442,0.000009797034,0.00002973385,0.000001081312,0.0000936966,0.00001652744,0.0001171295,0.000002123004,0.00000577147,0.00003507007],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9983599,0.000006610047,0.00004578194,0.000008151987,0.00003094343,0.00144945,0.00004829234,0.000001982492,0.00004893661],"genre_scores_gemma":[0.9997646,0.000004831543,0.0000588679,0.0000402418,0.00000706433,0.00003902291,0.00006291868,0.000009717831,0.00001275465],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2005077,"threshold_uncertainty_score":0.3868963,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.003221125034903623,"score_gpt":0.226143267694216,"score_spread":0.2229221426593123,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}